By: Sarah Beattie
Abbot has recently announced that as of September 30, 2025, the Libre 2 and Libre 3 CGM systems will be discontinued and replaced with the Libre 2+ and Libre 3+ CGM systems. As a diabetes education specialist, you wear many hats, including diabetes technology expert. Education, communication, and collaboration with those living with diabetes are the keys to a smooth and successful transition into updated technology.
Over 7 million people living with diabetes worldwide use a Libre Continuous Glucose Monitoring (CGM) system (1). The American Diabetes Association (ADA) 2025 Standards of Care recommends CGM as the standard of care for glucose monitoring for those on insulin therapy. The ADA also notes that CGM can be considered for those with diabetes who do not use insulin. (2)
Make Room for the Libre 2+ and Libre 3+ Systems
Since the early days of CGM technology, the Libre CGM systems have undergone several changes, and they recently announced the latest round of system improvements. They will be replaced with the Libre 2+ and Libre 3+ CGM systems.
What changes with New Libre 2+ and 3+:
- Selected insulin pump compatibility
- 15-day wear time (previously 14-day wear time)
- Approved for ages 2 years and older (previously approved for ages 4 years and older)
- More than 1000 mg of Vitamin C per day may affect glucose data (previous Vitamin C limit was 500 mg/day)
What stays the same:
- A handheld receiver (if needed for those without smartphone compatibility)
- High and low blood glucose alarms
- Sharing capability
- Libre 2+ still requires intermittent scanning every 8 hours (using the Libre 2 app or receiver)
- Size of sensors and application process
- 60-minute warm-up time
Action Needed – New Prescription
Individuals using these devices are advised to contact their healthcare provider to request a new prescription for the updated sensors. After September 30, 2025, any leftover 2 or 3 systems can still be used until their expiration date. The diabetes education specialist plays a crucial role in creating a plan to help navigate this technology transition.
New Universal Libre App
A new, universal updated phone app was released in April 2025. This changes the need for separate Libre 2 and Libre 3 apps to a universal Libre app compatible with the Libre 2, Libre 3, Libre 2+, and Libre 3+ sensors. The universal Libre app will remove the need for separate app downloads for those switching between the currently available Libre sensors. Additional features of the updated app include an easier-to-navigate platform, and users can silence alarms for a customized timeframe of up to six hours (3,4).
Keeping You Connected
Managing a chronic illness such as diabetes takes a team effort between those living with diabetes, the healthcare team, and family or caregivers. The LibreLinkUp app invites family members or caregivers who are helping with diabetes management to have access to glucose readings and alarms. Libre View is a cloud-based connected system between the person living with diabetes and the healthcare team. Using the Libre phone app, clients can permit healthcare providers to access their Libre CGM data to assist with creating an individualized plan of care. Abbot has also announced a collaboration with the Epic electronic medical records (EMR) system for data integration from LibreView into the EMR (1).
Libre 2+ and Libre 3+ Pump Integration
Libre 2+ and Libre 3+ can now integrate with selected automated insulin delivery (AID) systems. This will allow those using a Libre CGM to use an AID insulin pump as part of their glucose management plan. (5)
Here is a list of the current insulin pump compatibility:
- Libre 2+
-
- Omnipod 5 ® (Omnipod 5 app)
- Tandem t: slim X2 ™ (t:connect mobile app)
- Libre 3+
-
- Beta Bionics iLet Bionic Pancreas (iLet mobile app)
Over-the-Counter Libre Options
Over-the-counter (OTC) CGM is now an option for diabetes management. It is also available for those without diabetes who want to know more about glucose fluctuations. Libre now offers two OTC options, gaining approval in the US for use in 2024.
Libre Rio is an OTC CGM FDA approved for glycemic monitoring in adults 18 years and older who are not on insulin. This device can provide insightful data for those living with diabetes or prediabetes.
Libre Lingo is an OTC CGM in the health and wellness space, which is FDA approved for monitoring glucose variations to gain insight into the metabolic response to food and activity in those 18 years and older. (6)
The Bottom Line for Clinical Practice
Helping those living with diabetes navigate the changes to the Libre systems and apps can reduce frustration and data gaps. As diabetes education specialists and technology experts, you play a key role in preparing clients for upcoming changes to their diabetes technology. Understanding the differences between the Libre devices and what features are available will help create an individualized approach to diabetes care and education. If you want more information on improving your CGM data interpretation skills, check out the latest Tech Data Toolkit webinar.
References
- Abbot integrates Libre’s data with Epic’s electronic health record system, providing healthcare professionals seamless glucose monitoring information. (2025, April 9). Abbot. Retrieved May 8, 2025, from https://abbott.mediaroom.com/2025-04-29-Abbott-Integrates-Libres-Data-with-Epics-Electronic-Health-Record-System,-Providing-Healthcare-Professionals-Seamless-Glucose-Monitoring-Information#:~:text=About%20FreeStyle%20Libre:,more%20than%2040%20countries7
- American Diabetes Association Professional Practice Committee. (2025). Diabetes technology: Standards of care in diabetes – 2025. Diabetes Care, 48 (supplement 1), S146-S166. https://doi.org/10.2337/dc25-S007
- Abbot. (n. d.). Freestyle Libre apps. Abbot. https://www.freestyle.abbott/us-en/products/freestyle-libre-app.html
- HME News Staff. (2025, April 21). Abbot launches Libre app. HME News. https://www.hmenews.com/article/abbott-launches-libre-app
- Abbot. (n. d.). Compatible insulin pumps. Abbot. https://www.freestyle.abbott/us-en/products/insulin-pump-compatibility.html
- Bender, C., Vestergaard, P., & Cichosz, S. L. (2025). The history, evolution and future of continuous glucose monitoring (CGM). Diabetology, 6(3), 17. https://doi.org/10.3390/diabetology6030017
Tech Data Toolkit is ready for OnDemand Viewing!
Gain confidence in interpreting the Glucose Profile Report (AGP) & CGM data using a
person-centered approach
As diabetes technology is becoming commonplace in our practice, figuring out how to make sense of all the data can seem overwhelming. Join Diana Issacs and Coach Beverly for a truly unique learning experience.
Topics include:
- Review CGM key metrics and individualize time in-range goals
- Learn how to recognize patterns with the AGP report efficiently
- Utilize the AGP report as a discussion guide when meeting with a person with diabetes
- Recommend lifestyle and medication adjustments based on CGM data
- Strategies to recognize the expertise of the individual and collaborate on person-centered problem solving.
![](/wp-content/uploads/2023/01/insta-png-v5.png")
